Novel algorithm for more accurate calculation of renal function in adults with cancer

Annals of Pharmacotherapy

Volumn 42, Issue 12, 2008, Pages 1749-1757

  Holweger, Karin ^a,c   Lipp, Hans Peter ^a   Dietz, Klaus ^a   Hartmann, Joerg Thomas ^a   Bokemeyer, Carsten ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Department of Hospital Pharmacy ^*  (Germany)

Author keywords

trace protein; Algorithm; Cancer; Cockcroft Gault; Creatinine clearance; Cystatin C; Glomerular filtration rate

Indexed keywords

ALBUMIN; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CREATININE; CYSTATIN C; CYTARABINE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; UREA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALGORITHM; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; TESTIS CANCER;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTINEOPLASTIC AGENTS; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 54249126949     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L216     Document Type: Article

References (34)

1. Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34.
2. Jodrell DI, Egorin MJ, Canelta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
3. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl):S1-266.
4. 2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 2005;35:985-90.
5. 51Cr-EDTA. Clin Sci 1969;37:169-80.
6. Gutman Y, Gottschalk CW, Lassiter WE. Micropuncture study of inulin absorption in the rat kidney. Science 1965;147:753-4.
7. Perrone RD, Madias NE, Levey AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 1992;38:1933-53.
8. Holweger K, Bokemeyer C, Lipp HP. Accurate measurement of individual glomerular filtration rate in cancer patients: an ongoing challenge. J Cancer Res Clin Oncol 2005;131:559-67.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
10. Jelliffe RW. Creatinine clearance: bedside estimate (letter). Ann Intern Med 1973;79:604-5.
11. Calvert AH, Boddy A, Bailey NP, et al. Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 1995;22:91-8.
12. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-5.
13. Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol 2002;13:949-55.
14. Hoek FJ, Kemperman FA, Krediet RT. A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 2003;18:2024-31.
15. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004;64:25-30.
16. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002;40:221-6.
17. Priem F, Althaus H, Birnbaum M, Sinha P, Conradt HS, Jung K. Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. Clin Chem 1999;45:567-8.
18. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83.
19. Corcoran RM, Durnan SM. Albumin determination by a modified bromcresol green method. Clin Chem 1977;23:765-6.
20. Donadio C, Lucchesi A, Ardini M, Donadio E, Giordani R. Serum levels of beta-trace protein and glomerular filtration rate - preliminary results. J Pharm Biomed Anal 2003;32:1099-104.
21. Finney H, Newman DJ, Gruber W, Merle P, Price CP. Initial evaluation of cystatin C measurement by particle-enhanced immunonephelometry on the Behring nephelometer systems (BNA, BN II). Clin Chem 1997;43:1016-22.
22. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 1989;5:303-11.
23. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.
24. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84:1053-60.
25. Martin L, Chatelut E, Boneu A, et al. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer 1998;85:631-6.
26. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9.
27. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
28. World Health Organization. Obesity: preventing and managing the global epidemic report of a WHO consultation. Geneva: World Health Organization, 2000.
29. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
30. Dooley MJ, Poole SG, Rischin D, Webster LK. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer 2002;38:44-51.
31. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002;49:225-34.
32. Reyno LM, Egorin MJ, Canetta RM, et al. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 1993;11:1156-64.
33. Kleber M, Cybulla M, Bauchmuller K, Ihorst G, Koch B, Engelhardt M. Monitoring of renal function in cancer patients: an ongoing challenge for clinical practice. Ann Oncol 2007;18:950-8.
34. Nakai K, Kikuchi M, Fujimoto K, et al. Serum levels of cystatin C in patients with malignancy. Clin Exp Nephrol 2008;12:132-9.